Sales breakdown 2004 - Solvay

More documents

Recommendations

Info

Global Annual Report Solvay 2004 16 In 2004 the Group decided to consolidate ownership of all its pharmaceutical units under Solvay Pharmaceuticals SARL, a 100% Solvay-owned Luxembourg company. The Group has been concentrating the management of all its pharmaceutical activities in Solvay Pharmaceuticals since August 2004. The advantages for the Pharmaceuticals sector of effecting this concentration are: – simplification of its organization and major processes, improving its competitiveness; – greater autonomy, enabling it to take more rapidly the best decisions to expand its activities - internally by managing the Research pipeline and externally by acquisitions and other agreements - and accelerate its growth; and – better alignment of legal (ownership) and operational (management) structures, giving shorter, more efficient and less cumbersome decision-making and operational paths. The Chief Executive Officer of Solvay Pharmaceuticals, effective January 1, 2005, is Dr Werner Cautreels, previously Worldwide Head of Research and Development, who succeeded Mr Jürgen Ernst on the latter’s retirement. Developments by individual therapeutic fields and geographic areas Pharmaceutical Sector sales decreased slightly in 2004 on a constant currency basis, whilst falling by 5% in euros from 2003. Sales were affected by contract renegotiations with American primary distributors, which held down sales for a number of months, the continuing debate in the USA on female hormone replacement therapy and pressures on prices. European sales were also affected by falling consumption caused by funding deficits in health systems. The United States remains the sector’s largest market, with 31% of sales. Sales in NAFTA declined by 5% in US dollars for the reasons mentioned above. In Europe, notwithstanding restrictive policies, price controls and the promotion of generic drugs, the Sector made good progress, with sales up nearly 5% in several countries, such as Italy, Greece, Spain, Portugal, Belgium, the United Kingdom, Central and Eastern Europe and the Nordic and Baltic countries. Sales dipped, however, in France (-4%) and more significantly in the German-speaking countries. In our priority development zones of Asia (Japan, China, India), Middle East, Latin America (Brazil) and Canada, progress was varied. Beacon products in 2004 ANDROGEL ® , a male hormone product sold in North America, was Solvay’s top-selling drug in 2004. Behind ANDROGEL ® , the best sales figures were evenly distributed over all therapeutic areas. The largest growth was turned in by four products, PANTOLOC ® , INFLUVAC ® SERC ® and TEVETEN ® (+11% compared with 2003).
Pharmaceuticals Sector Flagship products 2004 Therapeutic field Products Markets 2004 sales in % of 2004 Differences EUR million sales 2004/2003 (%) Men’s health Androgel ® North America + Central and E. Europe, Middle East, S. Africa 231 13% – 8% Gastroenterology Pantoloc ® [1] Canada 139 8% + 12% Gastroenterology Creon ® Global 130 7% – 5% Women’s health Estratest ® North America 100 6% – 24% Mental health Serc ® Europe + Export 96 6% + 12% Gastroenterology Duphalac ® Europe + Export 78 4% + 3% Mental health Luvox ® Japan + Export 77 4% – 4% Immunology Influvac ® Europe + Export 76 4% + 12% Cardiology Teveten ® Global [3] 72 4% + 6% Mental health Marinol ® USA 63 4% – 10% Women’s health Prometrium ® [2] USA 59 3% – 23% Women’s health Duphaston ® Europe + Export 59 3% + 2% Cardiology Physiotens ® Europe + Export 58 3% – 3% Gastroenterology Duspatal ® Europe + Export 55 3% – 2% Gastroenterology Dicetel ® Europe + Export 44 3% + 7% 17 Global Annual Report Solvay 2004 [1] A registered trademark of Altana [2] A registered trademark of Schering Corp. [3] Except for USA, where rights were transferred to Biovail Agreements with world-class partners Cardiology Sales: EUR 205 million With Bristol-Myers Squibb (USA) for medication to treat obesity and cardiovascular risk factors Solvay Pharmaceuticals and Bristol-Myers Squibb have decided to join forces to develop and market a new and very promising compound in the cannabinoids field researched by Solvay. The highly innovative SLV 319 compound blocks the brain receptors that are responsible, among other things, for triggering the desire to eat. During the past 30 years obesity has been on the increase in both developed and developing countries. Today an estimated 300 million + adults have obesity problems. TEVETEN ® PLUS Solvay’s TEVETEN ® blood-pressure medication has been improved by the addition of a diuretic to give a new combined cardiovascular product, TEVETEN ® PLUS. First launched in Germany in 2002, it is now approved for use in 13 European countries. Marketing started in Denmark at the end of 2004, with other countries following in 2005. Approval has also been obtained in Canada, where TEVETEN ® PLUS was launched on July 6, 2004. MOSES Moses is the acronym for a research study into the occurrence and gravity of repeat strokes. Research results presented at an international symposium in Europe in September 2004 hold out considerable hope to the medical world and to patients treated with TEVETEN ® .
Page 1 and 2: Global Annual Report 2004 366 days
Page 3 and 4: 366 days of Innovation Acceleration
Page 5 and 6: Sales by sector [EUR million] Total
Page 7 and 8: Mission, Vision, Values 3 Global An
Page 9 and 10: Chairmen’s message and better to
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: Executive Committee and General Man
Page 15 and 16: Our strategy 11 Global Annual Repor
Page 17 and 18: Our Positions Essentials Apart from
Page 19: Pharmaceuticals Sector tential thro
Page 23 and 24: Pharmaceuticals Sector with the exc
Page 25 and 26: Pharmaceuticals Sector Pharmaceutic
Page 27 and 28: Chemicals Sector rising market Key
Page 29 and 30: Chemicals Sector The “Electrochem
Page 31 and 32: Chemicals Sector 27 Global Annual R
Page 33 and 34: Plastics Sector io and realigning K
Page 35 and 36: Plastics Sector Vinyls (polyvinyl c
Page 37 and 38: Plastics Sector A number of growth
Page 39 and 40: New Business Development for growth
Page 41 and 42: Human Resources Greater listening a
Page 43 and 44: Human Resources European Works Coun
Page 45 and 46: Sustainable Development and consult
Page 47 and 48: Sustainable Development Strengtheni
Page 49 and 50: Management Report 2004 net income u
Page 51 and 52: SENSITIVITY TO ECONOMIC FACTORS The
Page 53 and 54: Consolidated balance sheet EUR mill
Page 55 and 56: IFRS valuation rules The main accou
Page 57 and 58: - Trade liabilities Trade liabiliti
Page 59 and 60: Information per segment for 2004 is
Page 61 and 62: (6) Other operating gains and losse
Page 63 and 64: The tax charge breaks down as follo
Page 65 and 66: (18) Acquisitions / sale of investm
Page 67 and 68: (22) Consolidation differences (goo
Page 69 and 70: (26) Inventories EUR million, at De
Page 71 and 72:
The amounts recorded in the balance
Page 73 and 74:
Group policy on insurance Solvay Gr
Page 75 and 76:
) Hedging forecast short /medium-te
Page 77 and 78:
The following amounts relating to J
Page 79 and 80:
List of fully consolidated Group co
Page 81 and 82:
Solvay Interox Ltd, Warrington 100
Page 83 and 84:
List of proportionately consolidate
Page 85 and 86:
SOUTH KOREA Daehan Specialty Chemic
Page 87 and 88:
Income statement of Solvay SA (summ
Page 89 and 90:
Information for shareholders SOLVAY
Page 91 and 92:
Shareholders and investors relation
Page 93:
Solvay SA Rue du Prince Albert, 33
show all

Sales breakdown 2004 - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?